Positrigo Analysis: $14M Raised
What is Positrigo?
Positrigo's NeuroLF system delivers functional brain imaging at a fraction of traditional PET costs. The device is FDA and CE cleared for clinical use in the US and Europe. It enables early detection of dementia and other neurological disorders through precise functional imaging.
Location
Zürich, Switzerland
Employees
11-50
Founded
2018
Funding Status
Series A
Product Features & Capabilities
- NeuroLF brain PET system
- FDA and CE cleared for clinical use
- Ultra-compact design
- Functional brain imaging for dementia and neurology
Use Cases
Diagnose Alzheimer’s disease in outpatient clinics; Detect early-stage dementia in patients with memory decline; Image brain function in neuro-oncology patients; Monitor movement disorders with functional imaging; Support epilepsy diagnosis through metabolic activity mapping
Other Considerations
FDA cleared for breakthrough brain PET system; CE marked in Europe; First US outpatient neurology clinic to purchase NeuroLF; First university medical center in Germany to receive NeuroLF; iF Design Award 2025 winner; Series B funding of CHF 5.5 million; Swiss Accelerator grant from Innosuisse; Partnered with Bottneuro for clinical research collaboration; Published proof-of-concept in Journal of Imaging; Completed exploratory clinical study with BPET device; Received European Innovation Council (EIC) funding for breakthrough technology
See something that needs updating? Suggest edits to this profile.